Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | EIF4E | P06730 | 2/20 | 0.33 |
| ▸ | IL2 | P60568 | 1/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12756319 | 0.90 | ANO1 (0.38) | ABL1DAGLAMEN1KMT2AANO1 | |
| SCHEMBL12830013 | 0.88 | RAB9A (0.41) | ABL1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL12756329 | 0.88 | DAGLA (0.38) | ABL1DAGLASMN1; SMN2POLBMEN1 | |
| SCHEMBL12756396 | 0.86 | ABL1 (0.39) | ABL1KMOSMN1; SMN2POLBMEN1 | |
| SCHEMBL1953507 | 0.84 | ANO1 (0.49) | MEN1KMT2AANO1 | |
| SCHEMBL12830946 | 0.80 | THRB (0.40) | ANO1LMNA | |
| SCHEMBL12756310 | 0.80 | ANO1 (0.38) | SMN1; SMN2MEN1KMT2AANO1MAPT | |
| SCHEMBL12756309 | 0.80 | RAB9A (0.43) | ABL1POLBMEN1KMT2AMAPT | |
| SCHEMBL12756328 | 0.79 | ANO1 (0.37) | ANO1MAPTLMNA | |
| SCHEMBL12830134 | 0.79 | FAAH (0.39) | SMN1; SMN2POLBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ABL1 4066/4885DAGLA 1436/4885KMO 4235/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ABL1 4066/4885DAGLA 1436/4885KMO 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.